Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.  
Home Contact us sitemap

Meningococcal meningitis caused by the bacterium Neisseria meningitides, is a serious infection of the fluid in the spinal cord and the fluid that surrounds the brain and can result in brain damage and even death.
The bacteria are spread by direct close contact with the discharges from the nose or throat of an infected person.
Meningococcal meningitis is most common in infants and children. People who have had close or prolonged contact with a patient with meningococcal meningitis are at increased risk.
Bacterial meningitis can be treated with antibiotics, but an early diagnosis and treatment is crucial.
To prevent the disease, vaccines are the best choice.

The vaccine against meningitis consists of highly purified polysaccharides that originate from the Meningococcal bacteria. Currently vaccines are produced against 4 serotypes, called A, C, Y and W135. The strains used for production are recommended by WHO/NICPBP and provided by NICPBP.
The production of Meningococcal vaccine starts with the passaging of the seed strain on solid medium and moves on to the inoculation and propagation in 60 L and for the final fermentation in 600 L.

After harvesting and inactivation of the meningococcal bacteria, the polysaccharide is extracted and purified performing different downstream operations. These production steps are applied separately for each of the four meningococcal strains.
Tianyuan produces 3 types of polysaccharide meningitis vaccines: one mono-valent: Men A, one di-valent: Men AC, and one tetra-valent: Men ACYW135 which are filled into vials and lyophilized in freeze-dryers. Tianyuan also provides the reconstitution solution. This process allows an excellent shelf-life of the product. Finally, the vaccine quality is checked and then marketed after approval by the national regulatory authority (SFDA).
For the future it is planned to provide multi-dose vials of Men AC PS vaccine to meet national and international market requirements.
In China serotype A and C are prevalent, however the Men ACYW135 PS vaccine is the best choice to get vaccinated.

Tianyuan¡¯s Meningococcal Polysaccharide Vaccine YUNAONING is available as divalent (AC) or quadrivalent (ACYW135) formulation by the 2008. The vaccines consists of highly purified polysaccharides of the different meningococcal serogroups.
Although mostly serogroups A and C are prevalent in China, the quadrivalent vaccine provides additional protection. Both vaccines are high-quality vaccines. Tianyuan aspires to get the WHO-prequalification for its vaccines.

Copyright(C)2008,Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. All Rights Reserved.
 Supported by  ChinaPharmNet Toocle